The Pathologist and Toxicologist in Pharmaceutical Product Discovery

Abstract

Significant change is occurring in the drug discovery paradigm; many companies are utilizing dedicated groups from the toxicology/ pathology disciplines to support early stage activities. The goal is to improve the efficiency of the discovery process for selecting a successful clinical candidate. Toxicity can be predicted by leveraging molecular techniques via rapid high-throughput, low-resource in vitro and in vivo test systems. Several important activities help create a platform to support rapid development of a new molecular entity. The proceedings of this symposium provide excellent examples of these applied concepts in pharmaceutical research and development. Leading biopharmaceutical companies recognize that a competitive advantage can be maintained via rapid characterization of animal models, the cellular identification of therapeutic targets, and improved sensitivity of efficacy assessment. The participation of the molecular pathologist in this quest is evolving rapidly, as evidenced by the growing number of pathologists that interact with drug discovery organizations.

Keywords

Pathologist toxicologist pharmaceutical discovery efficacy models

References

Balwierz P. and Bunch T. (1998). An in situ micronucleus assay: Implications for drug discovery. Environ. Mol. Mutagen 31(suppl. 29): 3.

Davila J. and Morris D. (1999). Analysis of cytochrome P450 and phase II conjugating enzyme expression in adult male rat hepatocytes. In Vitro Cell. Dev. Biol. 35: 1-11 (in press).

International Conference on Harmonisation (March 1995). Fed. Register 60(40): 11274-11275.

Phillips J. , Gibson W. , Hard G. , and Alden C. (1990). Survey of QSAR and in vitro approaches for developing non-animal methods to supersede the in vivo LD50 test. Food Chem. Toxicol. 28: 375-394.